Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adoptEITF, aflibercept, allopurinol, andEITF, androgen, arcalysttm, ARCALYSTTMin, arrange, arrangement, ARVO, beotherthan, blinded, bound, Brazil, breach, calledVelocImmune, Canada, choose, concentration, corroboration, cut, delinquent, died, disagree, dispute, dissolution, docetaxel, drafted, driven, economic, elbow, ensuing, entirety, exempt, fight, filer, front, gemcitabine, Germany, glucocorticoid, greatest, hedge, imdertaken, IND, indirectly, infection, inflow, inRule, instability, IntegratedFramework, intestinal, intraarticular, intracellulare, inWet, Israel, itsVelociGenetechnology, itsVelocImmune, Japanese, KGaA, Kingdom, knowledge, land, landscape, launch, longest, mark, Mexico, minimal, mitigate, mycobacteria, mycobacterium, NE, nonfinancial, NY, ofEfficacy, ofEITF, ofRegulation, ordinary, ourvelocigene, OurVelociGeneplatform, ourVelociGenetechnology, ourVelocImmune, ourVelocImmunehuman, ourVelocImmunemice, ourVelocImmunetechnology, oversee, paper, perforation, persistent, pneumoniae, polymayalgia, preceding, priority, prohibit, prohibition, proportionally, proportionately, proprietaryVelociGene, ranibizumab, recommended, refinance, refinancing, reformatted, remediate, remediation, repay, resolve, robust, screening, seasoned, shell, slated, sliding, slight, solicitation, span, standstill, StatementNo, suspected, technologyVelocImmune®and, theVelocImmune, TheVelocImmunemice, TheVelocImmunemouse, theVelocImmunetechnology, TheVelociMousetechnology, thirty, thisForm, timeline, toVelocImmuneand, UK, unblinded, uncommon, undertaken, underwriter, underwritten, unpaid, upfront, uric, VIEW, wider, winding, worse, Xoma
Removed:
achievement, approximate, bore, calendar, ciliary, CNTF, compounded, enterprise, Eric, flexibility, forgave, guidance, hurt, integration, LIBOR, loan, neurotrophic, notified, NW, obesity, older, proceed, receiving, repayment, replenishment, represented, Retainer, Shooter, slightly, spectrum, threshold, updated, velocigene
Filing tables
Filing exhibits
- 10-K Annual report
- 3.1 EX-3.1: Restated Certificate of Incorporation
- 10.18 EX-10.18: Discovery and Preclinical Development Agreemnet
- 10.19 EX-10.19: License and Collaboration Agreement
- 10.20 EX:10.20: Stock Purchase Agreement
- 10.21 EX-10.21: Investor Agreement
- 12.1 EX-12.1: Statement Re: Computation of Ratio of Earnings to Combined Fixed Charges
- 23.1 EX-23.1: Consent of Pricewaterhousecoopers LLP
- 31.1 EX-31.1: Certification
- 31.2 EX-31.2: Certification
- 32 EX-32: Certification
REGN similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-50480, 33-85330, 33-97176, 333-33891, 333-80663, 333-61132, 333-97375, and 333-119257) and on Form S-3 (Nos. 333-74464 and 333-121225) of Regeneron Pharmaceuticals, Inc., of our report dated February 27, 2008 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
PricewaterhouseCoopers LLP |
New York, New York
February 27, 2008
February 27, 2008